Atossa Therapeutics (ATOS) Other Non-Current Liabilities (2013 - 2014)
Atossa Therapeutics (ATOS) posted quarterly Other Non-Current Liabilities of $76025.0 for Q4 2014, up 685.3% year-over-year from $9681.0 in Q4 2013, and up 685.3% quarter-over-quarter from $9681.0 in Q4 2013.
Atossa Therapeutics (ATOS) Other Non-Current Liabilities (2013 - 2014) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Other Non-Current Liabilities for 2 consecutive years, with $76025.0 the latest figure, recorded in Q4 2014.
- In Q4 2014, Other Non-Current Liabilities rose 685.3% year-over-year to $76025.0; the TTM figure through Dec 2014 stood at $76025.0 (up 685.3% YoY), while the FY2014 annual figure was $76025.0, up 685.3% from the prior year.
- Other Non-Current Liabilities advanced to $76025.0 in Q4 2014 per ATOS's latest filing, from $9681.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $76025.0 in Q4 2014 and bottomed at $9681.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 76,025.00 |
| Dec 31, 2013 | 9,681.00 |